Full name
"PHARMA2PHARMA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
uses securityreCAPTCHA
"PHARMA2PHARMA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
UL. KLAUDYNY 38 / 117, 01-684 WARSZAWA
TAX ID5272531180
Rate company:
"PHARMA2PHARMA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
TAX ID5272531180
KRS0000275687
Share capital100,000.00 zł
address
UL. KLAUDYNY 38 / 117, 01-684 WARSZAWA
Website
www.pharma2pharma.plCategories
Main category
Is this your company?Update company information to get new customers, get notified of new reviews, and more!
Register Data
NIP
5272531180
REGON
140861765
KRS
0000275687
Legal form
limited liability company
Register Address
UL. KLAUDYNY 38 / 117, 01-684 WARSZAWA
Date of registration in KRS
2007-03-02
Date of commencement of economic activity
2007-03-02
Act signature
WA.XII NS-REJ.KRS/68184/20/885/ADE
Website
WWW.PHARMA2PHARMA.PL
Pkd codes
82.30.Z - Activities related to organizing fairs, exhibitions, and congresses
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
46 - Wholesale trade
47 - Retail trade
62.0 - Activities related to programming, IT consulting, and related activities
70 - Head office activities and management consultancy
73 - Advertising, market research and public relations
74 - Other professional, scientific and technical activities
79 - Tourism activities, travel agency services, and other services related to booking and reservation activities
93 - Sports, entertainment, and recreational activities
Payer VAT status
Active
Vat list bank account(s)
PL82 1020 1127 0000 1602 0108 2791 
PL80 1020 1127 0000 1902 0145 4578 PL59 1020 1127 0000 1102 0261 5177 PL29 1020 1127 0000 1802 0160 9775 Show more bank accounts from VAT list (1)
Financial data
Net sales [PLN]
Gross profit / loss [PLN]
Automatically generated based on financial statements from KRS Registry
| 2021 | 2022 | 2023 | ||
|---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss)  | 0,2 | -0 | -0,1 | -121,1 |
EBITDA | 0,2 | -0,1 | -0,1 | -85,5 |
Short time liabilities | 0,2 | 0,3 | 0,3 | -2,1 |
Equity capital | 1,3 | 1,2 | 1,1 | -8,7 |
Operating profit (EBIT) | 0,2 | -0,1 | -0,1 | -85,5 |
Assets | 1,7 | 1,6 | 1,7 | 7 |
Net profit (loss) | 0,2 | -0 | -0,1 | -121,1 |
Cash | 1 | 0,7 | 0,2 | -68,7 |
Net income from sale | 1,7 | 0 | 0 | -100 |
Liabilities and provisions for liabilities | 0,4 | 0,4 | 0,6 | 61,7 |
Working assets | 1,5 | 1,3 | 1,3 | 5,3 |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | 12,3 | -4 | -9,7 | -5,7 |
Equity capital to total assets | 74,5 | 77,7 | 66,3 | -11,4 |
Gross profit margin | 12,3 | -1310,5 | -1322,8 | |
EBITDA Margin | 13,7 | -1492,6 | -1506,3 | |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 37 | 28 637 | 2 147 483 648 | 2 147 455 011 |
Current financial liquidity indicator | 0,8 | |||
Net dept to EBITDA | -3.1480660438537598 | 6.836939811706543 | -3.0127904415130615 | -9,8 |
Financial statements
01-01-2023 - 31-12-2023
Annual financial report
Download xml01-01-2023 - 31-12-2023
Annual financial report
Download pdf01-01-2023 - 31-12-2023
Resolution or decision approving the annual financial statements
Download pdf01-01-2023 - 31-12-2023
Activity report
Download pdfShow more (1)
uses security reCAPTCHA
Opinions
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane
0/ 5.0
How do you rate this company?
Your opinion matters to us.